PL3592732T3 - Wytwarzanie krystalicznego produktu farmaceutycznego - Google Patents
Wytwarzanie krystalicznego produktu farmaceutycznegoInfo
- Publication number
- PL3592732T3 PL3592732T3 PL18709661.5T PL18709661T PL3592732T3 PL 3592732 T3 PL3592732 T3 PL 3592732T3 PL 18709661 T PL18709661 T PL 18709661T PL 3592732 T3 PL3592732 T3 PL 3592732T3
- Authority
- PL
- Poland
- Prior art keywords
- manufacture
- pharmaceutical product
- crystalline pharmaceutical
- crystalline
- product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20175202 | 2017-03-07 | ||
| PCT/FI2018/050143 WO2018162793A1 (en) | 2017-03-07 | 2018-02-27 | Manufacture of a crystalline pharmaceutical product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3592732T3 true PL3592732T3 (pl) | 2025-06-30 |
Family
ID=61599196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18709661.5T PL3592732T3 (pl) | 2017-03-07 | 2018-02-27 | Wytwarzanie krystalicznego produktu farmaceutycznego |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11168058B2 (pl) |
| EP (2) | EP4559527A3 (pl) |
| JP (1) | JP7157071B2 (pl) |
| KR (3) | KR20250065940A (pl) |
| CN (4) | CN121181479A (pl) |
| AU (1) | AU2018229817B2 (pl) |
| BR (1) | BR112019018458A2 (pl) |
| CA (1) | CA3055019A1 (pl) |
| CL (2) | CL2019002540A1 (pl) |
| DK (1) | DK3592732T3 (pl) |
| EA (1) | EA201992103A1 (pl) |
| ES (1) | ES3027971T3 (pl) |
| FI (1) | FI3592732T3 (pl) |
| HR (1) | HRP20250684T1 (pl) |
| HU (1) | HUE071505T2 (pl) |
| LT (1) | LT3592732T (pl) |
| MX (1) | MX2019010452A (pl) |
| PL (1) | PL3592732T3 (pl) |
| PT (1) | PT3592732T (pl) |
| RS (1) | RS66855B1 (pl) |
| SI (1) | SI3592732T1 (pl) |
| UA (1) | UA126071C2 (pl) |
| WO (1) | WO2018162793A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3759076A1 (en) | 2018-02-27 | 2021-01-06 | Sandoz AG | Crystalline form ii of darolutamide |
| WO2020157699A1 (en) | 2019-01-30 | 2020-08-06 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
| EP3993779A1 (en) * | 2019-07-02 | 2022-05-11 | Orion Corporation | Pharmaceutical composition of darolutamide |
| WO2022036782A1 (zh) * | 2020-08-18 | 2022-02-24 | 拜耳消费者护理股份有限公司 | 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途 |
| WO2022144926A1 (en) * | 2020-12-31 | 2022-07-07 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of amorphous n-{(2s)-1-[3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide |
| MX2024009980A (es) | 2022-02-28 | 2024-08-26 | Quim Sintetica S A | Forma cristalina de darolutamida. |
| WO2025229051A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with antiandrogen agent |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006307470A1 (en) * | 2005-10-27 | 2007-05-03 | Lupin Limited | Pharmaceutical formulation of losartan |
| EP2168601B1 (en) * | 2007-05-28 | 2013-08-21 | Mitsubishi Shoji Foodtech Co., Ltd | Spherical mannitol crystal particle |
| WO2010084515A2 (en) | 2009-01-23 | 2010-07-29 | Glenmark Generics Limited | A process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof |
| US20100234469A1 (en) * | 2009-03-12 | 2010-09-16 | Medichem, S.A. | New Crystals Of A Benzoylbenzeneacetamide Derivative |
| AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| CA2831338C (en) * | 2011-04-21 | 2018-07-17 | Orion Corporation | Androgen receptor modulating carboxamides |
| KR20140030169A (ko) * | 2011-05-04 | 2014-03-11 | 머크 샤프 앤드 돔 코포레이션 | 약물 물질, 제약 조성물 및 그의 제조 방법 |
| EP3250554B1 (en) * | 2015-01-30 | 2022-05-18 | Orion Corporation | A carboxamide derivative and its diastereomers in stable crystalline form |
| CN109641851B (zh) | 2016-08-26 | 2022-09-02 | 拜耳消费者护理股份有限公司 | 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途 |
| CN107602471B (zh) | 2017-09-22 | 2021-04-27 | 成都恒汇化成医药科技有限公司 | 一种达罗鲁胺的晶型制备方法 |
-
2018
- 2018-02-27 PL PL18709661.5T patent/PL3592732T3/pl unknown
- 2018-02-27 AU AU2018229817A patent/AU2018229817B2/en active Active
- 2018-02-27 KR KR1020257014818A patent/KR20250065940A/ko active Pending
- 2018-02-27 CN CN202511412504.9A patent/CN121181479A/zh active Pending
- 2018-02-27 CN CN202511412369.8A patent/CN121021396A/zh active Pending
- 2018-02-27 PT PT187096615T patent/PT3592732T/pt unknown
- 2018-02-27 SI SI201831234T patent/SI3592732T1/sl unknown
- 2018-02-27 WO PCT/FI2018/050143 patent/WO2018162793A1/en not_active Ceased
- 2018-02-27 HR HRP20250684TT patent/HRP20250684T1/hr unknown
- 2018-02-27 RS RS20250547A patent/RS66855B1/sr unknown
- 2018-02-27 FI FIEP18709661.5T patent/FI3592732T3/fi active
- 2018-02-27 CA CA3055019A patent/CA3055019A1/en active Pending
- 2018-02-27 CN CN201880016135.3A patent/CN110382467B/zh active Active
- 2018-02-27 HU HUE18709661A patent/HUE071505T2/hu unknown
- 2018-02-27 EP EP25162995.2A patent/EP4559527A3/en active Pending
- 2018-02-27 KR KR1020247018685A patent/KR20240096691A/ko not_active Ceased
- 2018-02-27 KR KR1020197029193A patent/KR102676383B1/ko active Active
- 2018-02-27 EA EA201992103A patent/EA201992103A1/ru unknown
- 2018-02-27 ES ES18709661T patent/ES3027971T3/es active Active
- 2018-02-27 DK DK18709661.5T patent/DK3592732T3/da active
- 2018-02-27 BR BR112019018458-9A patent/BR112019018458A2/pt not_active Application Discontinuation
- 2018-02-27 US US16/491,642 patent/US11168058B2/en active Active
- 2018-02-27 JP JP2019548560A patent/JP7157071B2/ja active Active
- 2018-02-27 EP EP18709661.5A patent/EP3592732B1/en active Active
- 2018-02-27 LT LTEPPCT/FI2018/050143T patent/LT3592732T/lt unknown
- 2018-02-27 CN CN202511412433.2A patent/CN121202788A/zh active Pending
- 2018-02-27 UA UAA201910164A patent/UA126071C2/uk unknown
- 2018-02-27 MX MX2019010452A patent/MX2019010452A/es unknown
-
2019
- 2019-09-04 CL CL2019002540A patent/CL2019002540A1/es unknown
-
2023
- 2023-09-20 CL CL2023002780A patent/CL2023002780A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3592732T (lt) | Kristalinio farmacinio produkto gamyba | |
| SI3087852T1 (sl) | Oralni vrečast proizvod, ki ima pravokotno obliko | |
| IL265239A (en) | A process for the production of a solid pharmaceutical preparation | |
| SG11201702299SA (en) | Pharmaceutical product | |
| GB201706327D0 (en) | A pharmaceutical compound | |
| EP3154732A4 (en) | Method of producing a powder product | |
| ZA201806687B (en) | Manufacture of a cereal-based lactic acid-fermented product | |
| ZA201805608B (en) | Production of crystalline cellulose | |
| GB201522771D0 (en) | Crystalline form of a phosphate derivative | |
| SG11201610959PA (en) | Novel composition of a confectionery product | |
| IL268344A (en) | A system for use in a pharmaceutical product | |
| EP3426646A4 (en) | PRODUCTION EQUIPMENT FOR THE PRODUCTION OF A CAPROLACTONE | |
| PL3355870T3 (pl) | Sposób wytwarzania kompresowanych tabletek | |
| IL275381A (en) | A process for the preparation of Crisborole | |
| GB201412683D0 (en) | Forming a ceramic product | |
| IL268456B (en) | A new process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes | |
| PT3262905T (pt) | Método de calibração de um distribuidor | |
| ZA201800264B (en) | Packaging for a medical product | |
| IL273553A (en) | A method for preparing a pharmacy product | |
| GB201610867D0 (en) | Crystalline forms of a therapeutic compound and processes for their preparation | |
| PL3043652T3 (pl) | Proces sporządzania wyrobów cukierniczych | |
| PT3665183T (pt) | Método de preparação de uma composição farmacêutica | |
| IL256429B (en) | A production line for the production of medical products, and a production site containing such a production line | |
| ZA201708479B (en) | A confectionery product | |
| EP3060196A4 (en) | Manufacture of a pharmaceutical product |